MannKind Corporation (MNKD) SEC Filings & Earnings Calls

Potential dilution from future equity issuance.

“Prospectus supplement for common stock issuance.”

Dependence on Furoscix for growth; gross margin pressure from product mix

“Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza.” · word for word

Increased SG&A expenses for product launches

“Selling, general and administrative expenses were $58.3 million...increase of 84%...related to costs associated with the promotion and support of Furoscix, as well as expanding our field-based teams” · word for word

Dependence on United Therapeutics for Tyvaso DPI royalties

“If United Therapeutics reduces its commercial emphasis on Tyvaso DPI, our revenues could decline materially.” · word for word

High debt and interest expense

“Interest expense increased by $11.6 million for the three months ended June 30, 2026 compared to the same period in the prior year.” · word for word

Tariff exposure on imported components

“Current or future tariffs will also result in increased manufacturing expense.” · word for word

CVR payment obligation

“Milestone 1 under the CVR Agreement was achieved on July 23, 2026, which will necessitate an aggregate payout of approximately $44.8 million in the third quarter of 2026.” · word for word

Significant dilution from 12.85M new shares/warrants

“10.44M shares + 2.41M pre-funded warrants issued at ~$3.89”

CVR payment obligation of $45M creates near-term cash need

“funding the Company's $45.0 million contingent value rights payment obligation” · word for word

UT Pipeline Cannibalization Risk

“If United Therapeutics reduces its commercial emphasis on Tyvaso DPI, our revenues could decline materially.” · word for word

Tariff Cost Pressure

“Current or future tariffs will also result in increased manufacturing expense... our ability to pass increased costs to customers is limited.” · word for word

High Debt and Interest Expense

“Interest expense increased by $2.8 million... due to new term loans with an aggregate principal amount of $325.0 million.” · word for word

V-Go Demand Decline

“Gross revenue from sales of V-Go decreased by $1.5 million, or 23%” · word for word

Gross margin pressure from Furoscix integration; lower margin product mix.

“Gross margin decreased due to inclusion of Furoscix (on-body infusor), which has a lower gross margin than Afrezza.”

Operating expense growth outpacing revenue growth; SG&A +116% vs revenue +15%.

“SG&A expenses $54.1M, +116% vs prior year.”

R&D expense increase due to pipeline investment; clinical trial discontinuation risk.

“R&D expenses $27.6M Q4 (+148%) due to ICoN-1 study discontinued, clinical production scale-up for MNKD-201.”

FDA approval dependency for Afrezza pediatric and Furoscix ReadyFlow.

“PDUFA dates May 29, 2026 and July 26, 2026; non-approval would impact growth expectations.”

Manufacturing concentration risk

“Currently, our manufacturing facility in Connecticut is the sole location for the manufacturing of Afrezza and Tyvaso DPI.” · word for word

Dependence on collaborators and third-party manufacturers

“we have exclusive supply arrangements with the contract manufacturers that produce V-Go and Furoscix.” · word for word

Pipeline setback with MNKD-101 failure.

“Phase 3 trial discontinued due to futility, no sputum culture conversion.”

Impairment of investment and acquisition-related debt increase financial risk.

“Impairment of available-for-sale investment $6.4M; borrowed $250M in delayed draw term loans.”

Tariff exposure on V-Go supply chain

“V-Go is wholly manufactured on our behalf by contract manufacturers located in China. ... any tariffs that apply to imported goods from China could materially and adversely affect our margins on V-Go sales.” · word for word

Debt and liquidity risk from scPharma acquisition

“In October 2025, we borrowed an additional $250.0 million in delayed draw term loans under the Blackstone Credit Facility to fund the acquisition of scPharma.” · word for word

Single-source insulin supply risk

“Currently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar.” · word for word